Results 21 to 30 of about 7,686 (201)
Cardiology and Therapy, 2020 Introduction Clinicians, payers, guideline committees, and policymakers support the use of high-intensity statins in patients at high risk for complications of cardiovascular disease (CVD).
Michael J. Koren +9 more
doaj +1 more source
Reviews in Cardiovascular Medicine, 2023 Background: Evolocumab has been demonstrated to significantly reduce ischemic cardiovascular events in patients with stable coronary heart disease. However, it is currently unclear whether this benefit extends to patients with acute coronary syndrome ...
Yahao Zhang +7 more
doaj +1 more source
Roles of reconstituted high-density lipoprotein nanoparticles in cardiovascular disease: A new paradigm for drug discovery [PDF]
, 2020 Epidemiological results revealed that there is an inverse correlation between high-density lipoprotein (HDL) cholesterol levels and risks of atherosclerotic cardiovascular disease (ASCVD).
Huang, Hui +3 more
core +2 more sources
Cost-Effectiveness of LDL-C Lowering With Evolocumab in Patients With High Cardiovascular Risk in the United States [PDF]
, 2016 Randomized trials have shown marked reductions in low-density lipoprotein cholesterol (LDL-C), a risk factor for cardiovascular disease (CVD), when evolocumab is administered.
Fonarow, G.C. +6 more
core +1 more source
BMJ Open, 2022 Objective The FOURIER trial showed a benefit of the PCSK9 inhibitor evolocumab over placebo with respect to cardiovascular outcomes in patients with cardiovascular disease. However, we observed some inconsistencies between the information in the Clinical
Ken Bassett +8 more
doaj +1 more source
The Efficacy and Safety of Four Novel PCSK9 Monoclonal Antibodies in Patients With Hypercholesterolemia: A Systematic Review With Network Meta-Analysis and Trial Sequential Analysis. [PDF]
Cardiovasc TherAim This network meta‐analysis (NMA) evaluated four novel proprotein convertase subtilisin/kexin type 9 (PCSK9) monoclonal antibodies for hypercholesterolemia management, comparing their lipid‐lowering efficacy and safety. Methods We systematically identified randomized controlled trials employing the frequentist NMA method to assess reductions in low ...
Wang S, Li C, Fan D.
europepmc +2 more sources
Евразийский Кардиологический Журнал, 2020 Aim: to evaluate the efficacy and safety of the use of evolocumab in patients with familial hypercholesterolemia (FH).Materials and methods: Fifteen patients with a definite FH were treated with PCSK9 inhibitors, in 11 patients with a history of CAD ...
V. A. Korneva +2 more
doaj +1 more source
The High Price of Interrupted Follow‐Up: Catastrophic Progression of Homozygous Familial Hypercholesterolemia—A Case Report and Literature Review [PDF]
Clin Case RepABSTRACT Familial hypercholesterolemia (FH) is the most common monogenic lipid disorder, primarily resulting from mutations in LDLR, APOB, and PCSK9 genes. These mutations cause persistently high levels of low‐density lipoprotein cholesterol (LDL‐C), predisposing affected individuals to premature atherosclerotic cardiovascular disease (ASCVD ...
Dastjerdi P +5 more
europepmc +2 more sources
Early effects of PCSK9 inhibitors: evolocumab versus alirocumab [PDF]
Kosin Medical JournalBackground The significance of risk modification in patients with acute coronary syndrome (ACS) is well recognized; however, the optimal timing for adminstering PCSK9 inhibitors remains unclear. Additionally, the lipid-lowering efficacy of evolocumab and
Su-Hyun Bae +5 more
doaj +1 more source
Metabolic effects of PCSK9 inhibition with Evolocumab in subjects with elevated Lp(a)
Lipids in Health and Disease, 2020 Background Epidemiological studies substantiated that subjects with elevated lipoprotein(a) [Lp(a)] have a markedly increased cardiovascular risk. Inhibition of proprotein convertase subtilisin/kexin type 9 (PCSK9) lowers both LDL cholesterol (LDL-C) as ...
Xiang Zhang +3 more
doaj +1 more source